Tirzepatide 5mg/10mg/15mg/20mg/30mg/40mg/50mg/60mg

Tirzepatide is the world's first and currently the only glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly, it was approved for marketing in China on May 21, 2024, and officially launched on January 2, 2025. It is suitable for adult patients with type 2 diabetes whose blood sugar is still poorly controlled by metformin and/or sulfonylurea drugs on the basis of diet control and exercise. Mechanism of Action: Tirzepatide integrates the effects of two incretin hormones, GIP and GLP-1, into one molecule, and provides more clinical effects by activating these two peptide hormone receptors at the same time. Among them, the activation of GLP-1 receptors delays gastric emptying, reduces appetite, lowers blood sugar and improves insulin sensitivity; while the activation of GIP receptors enhances insulin secretion, reduces glucagon release and promotes fat metabolism. Clinical Trials & Efficacy: In a series of clinical trials called SURPASS, Tirzepatide showed excellent efficacy. In the treatment of patients with type 2 diabetes, after monotherapy with Tirzepatide, the average reduction in glycated hemoglobin (HbA1c) in patients reached 2.0% to 2.5%. Among them, the high-dose Tirzepatide group (15mg) was significantly better than the 1mg Semaglutide group (HbA1c reduction of 1.9% vs 2.5%). Tirzepatide also showed outstanding effects in weight loss. In the SURMOUNT trial (for obese or overweight non-diabetic patients), the average weight loss of patients in the high-dose (15mg) group was 20.9%, with a weight loss of approximately 22.5 kg; the weight loss in the medium-dose (10mg) group was 19.5%, with a weight loss of approximately 20.9 kg. This significant weight loss effect has made Tirzepatide a hot topic in the field of weight loss. In addition, Tirzepatide may also have more systemic benefits. For example, Tirzepatide has also shown great advantages and potential in combating heart failure and reducing cardiovascular mortality. It can reduce insulin resistance, improve myocardial metabolism, and also has anti-inflammatory and anti-oxidative stress effects, which can protect the myocardium. The effects of Tirzepatide on weight loss and blood pressure reduction also reduce the workload on the heart. Hot-selling Dosages: Tirzepatide 5mg, Tirzepatide 10mg, Tirzepatide 15mg, Tirzepatide 20mg, Tirzepatide 30mg, Tirzepatide 40mg, Tirzepatide 50mg, Tirzepatide 60mg. We can also customize it according to customers' specific needs and quantities. Welcome to contact us! Contact Information: [email protected]; +86 15840669648 (WhatsApp)